Funazol M Tablet 150 mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Oral formulations are rapidly and almost completely absorbed; therefore, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. ○ Adults 1. Vaginal candidiasis: Administer a single oral dose of 150 mg of fluconazole. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this drug is 400 mg once on the first day, followed from the next day by 200 mg once daily. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment should be determined according to the clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this drug is 400 mg once on the first day, followed from the next day by 200-400 mg once daily. The duration of treatment is determined by the clinical and mycological response, but treatment should generally continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this drug once daily indefinitely after the patient has completed primary treatment. 5. Prevention of fungal infections in immunocompromised patients at risk of fungal infections due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this drug once daily, depending on the patient's degree of risk for fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infections, such as those undergoing bone marrow transplantation, who have severe neutropenia or are expected to have prolonged neutropenia. In such patients, administer 400 mg starting 5-6 days before the anticipated onset of neutropenia, and continue administering 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis, administer 150 mg once weekly until the fingernails or toenails have regrown (until uninfected new nails have grown). New fingernails generally take 3-6 months to grow, and toenails take approximately 6-12 months; the growth rate may vary from person to person and with age. In some cases, the fingernails or toenails may remain damaged even after successful treatment with long-term administration. Dermatophyte infections of the skin, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this drug is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, treatment of athlete's foot may need to continue for 6 weeks depending on the course of the condition. For pityriasis versicolor, administer 50 mg once daily for 2-4 weeks. ○ Older adults If renal function is normal, the usual adult dose is administered. In patients with renal impairment (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This drug is excreted mainly in the urine unchanged. No dosage adjustment is necessary when administering a single dose; however, when multiple doses are required, administer the usual dose only on the first day and adjust the dose from the next day as follows. Creatinine clearance (mL/min) Recommended dose > 50 100 % of the usual dose ≤50 (not on dialysis) 50% of the usual dose Patients on hemodialysis 100 % of the usual dose after each hemodialysis session Patients receiving hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, administer a reduced dose according to creatinine clearance.

This medication is an azole antifungal agent used for the treatment of fungal infections. Firstly, patients who have hypersensitivity or allergies to azole medications should not use this medication. Pregnant women or women who may become pregnant, as well as nursing mothers, should avoid this medication. In addition, severe side effects may occur when taken with specific medications, so it should not be used in combination with terfenadine, cisapride, astemizole, erythromycin, and others. Patients with lactose intolerance or hereditary lactose degradation enzyme deficiency should also refrain from using this medication. Patients with kidney or liver function issues need to be cautious when taking this medication, as liver function may worsen, requiring regular check-ups. Patients with heart disease or electrolyte imbalances should exercise caution due to the risk of heart rhythm disturbances caused by this medication. This medication can interact with several other drugs, so if any other medications are currently being taken, it is essential to inform the doctor or pharmacist, and dosage adjustments or monitoring may be necessary. This medication is generally well tolerated; however, rare side effects such as blood abnormalities, liver damage, skin rash, and cardiac arrhythmias may occur, so if any unusual symptoms arise, immediate consultation with medical personnel is recommended. During pregnancy, there may be an increased risk of miscarriage or congenital abnormalities, so it should be avoided if planning a pregnancy or during pregnancy. Effective contraception should be used for one month after the last dose. Nursing mothers are also advised to avoid breastfeeding while taking this medication. Safety in children, particularly in infants under 6 months of age, has not been established, so it should be administered cautiously and only when necessary. Dizziness or seizures may occur while driving or operating machinery, requiring careful attention. In cases of overdose, hallucinations or abnormal behavior may occur, requiring immediate medical treatment, and supportive care, gastric lavage, and dialysis may be necessary to remove the drug.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizure, dizziness, paresthesia, dysgeusia, tremor, vertigo, Torsade de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, elevated ALT, elevated AST, increased serum alkaline phosphatase, cholestasis, jaundice, increased bilirubin, hepatic toxicity, liver failure, hepatocellular necrosis, hepatitis, hepatocyte damage, rash, pruritus, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial swelling, hair loss, drug reaction with eosinophilia and systemic symptoms (DRESS), myalgia, fatigue, malaise, asthenia, fever, adrenal insufficiency, hallucinations, paranoid behavior

This medication should be stored in a sealed container to protect it from air and moisture. The storage temperature should be kept between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance

Pink oblong tablets

Package unit

30 tablets/bottle - 30 tablets/bottle